Solid tumors are abnormal tissue without a liquid area. Most solid tumors are named for the location or type of cell in which they develop, such as breast cancer, prostate cancer, or skin cancer. While solid tumors can be benign, when malignant they are classified as solid tumor cancer.
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
Date: April 14, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify...
Date: February 24, 2022 Time: 7:00am (PST), 10:00am (EST) In oral cancer surgery, the ultimate goal is to obtain tumor-negative resection margins. Yet, tumor-positive resection margins (i.e....
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
Date: September 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) High-dimensional flow cytometry generates a wealth of data. Computational approaches can help to simplify the complexity of large d...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clini...
Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Date: June 30, 2021 Time: 7:00am (PDT), 8:00am (EDT) Join us to discover how Optical genome mapping (OGM) mapping can help you in the characterization of complex samples. OGM is a non-sequen...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Next-generation sequencing is transforming scientific research and testing. Thanks to large-scale cancer projects (e.g. The Cancer Genome Atlas - TCGA), the accumulated knowledge is now used...
Proximity Ligation Assay (PLA), is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of in...
5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Date: April 13, 2021 Time: 07:00am PST Trends continue towards the development of more sophisticated and physiologically relevant 3D in vitro models, such as stem cell-derived models, organo...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
Date: November 20, 2020 Time: 10:00am (PST), 1:00pm (EST) This webinar will provide an overview of the Bio-Techne technologies being used by Biopharma for the development of biomarkers and c...
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
Date: April 14, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify...
Date: February 24, 2022 Time: 7:00am (PST), 10:00am (EST) In oral cancer surgery, the ultimate goal is to obtain tumor-negative resection margins. Yet, tumor-positive resection margins (i.e....
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
Date: September 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) High-dimensional flow cytometry generates a wealth of data. Computational approaches can help to simplify the complexity of large d...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clini...
Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Date: June 30, 2021 Time: 7:00am (PDT), 8:00am (EDT) Join us to discover how Optical genome mapping (OGM) mapping can help you in the characterization of complex samples. OGM is a non-sequen...
Date: June 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Next-generation sequencing is transforming scientific research and testing. Thanks to large-scale cancer projects (e.g. The Cancer Genome Atlas - TCGA), the accumulated knowledge is now used...
Proximity Ligation Assay (PLA), is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of in...
5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Date: April 13, 2021 Time: 07:00am PST Trends continue towards the development of more sophisticated and physiologically relevant 3D in vitro models, such as stem cell-derived models, organo...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
Date: November 20, 2020 Time: 10:00am (PST), 1:00pm (EST) This webinar will provide an overview of the Bio-Techne technologies being used by Biopharma for the development of biomarkers and c...
Opens in a new windowOpens an external siteOpens an external site in a new window